Effects of chrysin loaded self‐nano emulsifying drug delivery system for the treatment of Alzheimer’s disease

Publisher:
Wiley
Publication Type:
Journal Article
Citation:
Alzheimer's & Dementia, 2024, 20, (Suppl 4), pp. e085599
Issue Date:
2024-12
Full metadata record
AbstractBackgroundAlzheimer’s disease (AD) is a type of degenerative disorder that affects the brain. There are various herbal drugs that have been tested for their effectiveness in treating AD, and chrysin is one of them. Chrysin is a polyphenolic flavonoid that has several neuroprotective effects, including reducing the levels of AChE enzyme, accumulated amyloid β, oxidative stress, and neuroinflammation. It is also inherently senolytic, which helps to lessen the impact of cellular aging. However, chrysin has a limited ability to dissolve and is not easily absorbed by the blood‐brain barrier, which can reduce its effectiveness.MethodWe have developed a self‐emulsifying drug delivery system (SNEDDS) for chrysin to address these issues using a Box‐Behnken design (BBD) approach. The pharmacokinetic studies showed that chrysin SNEDDS had significantly higher bioavailability than regular chrysin. The pharmacodynamic studies assessed cognitive and motor functions in rats.ResultSNEDDS has many advantages, including increased drug loading, ease of preparation, high stability, and increased bioavailability and blood‐brain barrier permeability. The optimized formulation of chrysin‐loaded SNEDDS resulted in a small droplet size, high drug loading, and good stability. The formulation was evaluated for its bioavailability, availability in the brain, and pharmacodynamic efficacy.ConclusionThe results showed that chrysin SNEDDS loaded significantly improved cognitive functions in AD‐induced rats at both low and high doses. The biochemical studies also demonstrated that chrysin SNEDDS loaded reduced the levels of AChE enzyme, amyloid β, oxidative stress, and neuroinflammation.
Please use this identifier to cite or link to this item: